---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-26-000055"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2026-07-29T10:15:13+00:00"
generated_at: "2026-07-29T10:20:11.586655+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Integra Q2 2026: Revenue $418.8M (+0.8%), Adj EPS $0.56 vs $0.45; reaffirms FY adj EPS $2.40-$2.50

## Summary
- Q2 revenue $418.8M (+0.8% reported, +0.7% organic); GAAP EPS $0.06 vs -$6.31; adjusted EPS $0.56 vs $0.45.
- Adjusted EBITDA $78.4M (18.7% of revenue) vs $71.2M (17.1%) in prior year.
- Specialty Surgery revenue $309.3M (+1.6% organic); Tissue Reconstruction $109.5M (-2.0% organic).
- Full-year reported revenue guidance narrowed to $1.654B-$1.695B (from $1.662B-$1.702B) due to FX; organic growth and adj EPS reaffirmed.
- Braintree facility producing; SurgiMend relaunch on track for Q4 2026.

## SEC filing metadata
- accession: 0000917520-26-000055
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2026-07-29T10:15:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752026000055/0000917520-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752026000055/iart-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-26-000055
- JSON: https://secwatch.observer/filing/0000917520-26-000055.json
- Plain text: https://secwatch.observer/filing/0000917520-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.